<DOC>
	<DOC>NCT02405598</DOC>
	<brief_summary>evaluate if beta 2-adrenergic agonist can have adjuvant effect to patients with infantile-onset Pompe disease under enzyme replacement therapy</brief_summary>
	<brief_title>Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>1. Confirm diagnosis as Pompe disease 2. age 2 years or above 3. under at least 1 year regular recombinant human acid alpha glucosidase, and no dosage/frequency change in recent 3 months 4. Provide inform consent 1. chronic heart disease such as arrhythmia, cardiomyopathy, cardiac infarction 2. history of seizure 3. history of diabetes mellitus 4. history of hyperthyroidism 5. hypokalemia 6. pregnant 7. allergy to Î²agonists 8. under medications including diuretics, digoxin, betablockers, etc</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>